Molecular Partners AG Logo

Molecular Partners AG

Clinical-stage company developing novel protein therapeutics for oncology.

MOLN | SW

Overview

Corporate Details

ISIN(s):
CH0256379097 (+1 more)
LEI:
875500AXMLDAZ4D21744
Country:
Switzerland
Address:
Wagistrasse 14, 8952 Schlieren

Description

Molecular Partners AG is a clinical-stage biopharmaceutical company pioneering the design and development of a novel class of protein therapeutics known as DARPin® therapies. DARPins (Designed Ankyrin Repeat Proteins) are a proprietary class of small, custom-built proteins engineered to bind to specific disease targets with high potency and specificity. The company leverages its platform to create multi-specific drug candidates capable of engaging multiple targets or pathways simultaneously. The development pipeline is primarily focused on advancing innovative treatments in oncology, with clinical programs targeting serious diseases such as acute myeloid leukemia (AML). The company's approach aims to address complex medical challenges by utilizing the unique properties of its engineered protein platform.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-07-07 07:25
Molecular Partners AG: Molecular Partners Successfully Completes the Launch of …
English 17.3 KB
2020-04-19 23:15
Molecular Partners Initiates Anti-COVID-19 Therapeutic Program Leveraging Multi…
English 12.0 KB

Automate Your Workflow. Get a real-time feed of all Molecular Partners AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Molecular Partners AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Molecular Partners AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-09-09 N/A Executive member Sell None 47,784.80 CHF
2024-09-09 N/A Executive member Sell None 13,822.40 CHF
2024-04-02 N/A Executive member Sell None 243,000.00 CHF
2023-11-01 N/A Executive member Buy None 31,760.55 CHF
2022-02-15 N/A Executive member Sell None 2,410,500.00 CHF
2022-02-15 N/A Executive member Sell None 1,607,000.00 CHF

Peer Companies

AVACTA GROUP PLC Logo
Clinical-stage biotech developing targeted oncology drugs with a proprietary platform.
United Kingdom
AVCT
AVADEL PHARMACEUTICALS PLC Logo
Biopharmaceutical company developing therapies for sleep disorders, focusing on narcolepsy.
United States of America
AVDL
Avalon GloboCare Corp. Logo
Develops cell-based immunotherapies and provides precision diagnostics and lab services.
United States of America
ALBT
Avidity Biosciences, Inc. Logo
Develops a class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs).
United States of America
RNA
Axogen, Inc. Logo
Develops and commercializes surgical solutions for peripheral nerve repair.
United States of America
AXGN
Axsome Therapeutics, Inc. Logo
A biopharmaceutical company developing therapies for central nervous system disorders.
United States of America
AXSM
AYTU BIOPHARMA, INC Logo
A specialty pharma company developing novel therapeutics for complex CNS diseases.
United States of America
AYTU
Azitra, Inc. Logo
Clinical-stage biopharma company developing microbiome-based therapies for skin diseases.
United States of America
AZTR
Bachem Holding AG Logo
A CDMO developing and manufacturing peptides and oligonucleotides for pharma and biotech.
Switzerland
BANB
Barinthus Biotherapeutics plc. Logo
Clinical-stage biopharma developing immunotherapies that guide T cells to control disease.
United States of America
BRNS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.